EGFR and non-small cell lung carcinoma: Small molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors are an effective treatment option for patients with non-small cell lung cancer (NSCLC) harboring a sensitizing EGFR mutation [1].